Santos RAS, et al. The renin-angiotensin system: going beyond the classical paradigms. Am J Physiol Heart Circ Physiol. 2019;316(5):H958–70. https://doi.org/10.1152/ajpheart.00723.2018.

Article  PubMed  PubMed Central  CAS  Google Scholar 

George AJ, Thomas WG, Hannan RD. The renin-angiotensin system and cancer: old dog, new tricks. Nat Rev Cancer. 2010;10(11):745–59. https://doi.org/10.1038/nrc2945.

Article  PubMed  CAS  Google Scholar 

Lever AF, et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet. 1998;352(9123):179–84. https://doi.org/10.1016/S0140-6736(98)03228-0.

Article  PubMed  CAS  Google Scholar 

Sobczuk P, et al. Anthracycline-induced cardiotoxicity and renin-angiotensin-aldosterone system-from molecular mechanisms to therapeutic applications. Heart Fail Rev. 2022;27(1):295–319. https://doi.org/10.1007/s10741-020-09977-1.

Article  PubMed  CAS  Google Scholar 

Silveira KD, et al. Beneficial effects of the activation of the angiotensin-(1–7) MAS receptor in a murine model of adriamycin-induced nephropathy. PLoS ONE. 2013;8(6):e66082. https://doi.org/10.1371/journal.pone.0066082.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Zong WN, et al. Regulation of angiotensin-(1–7) and angiotensin II type 1 receptor by telmisartan and losartan in adriamycin-induced rat heart failure. Acta Pharmacol Sin. 2011;32(11):1345–50. https://doi.org/10.1038/aps.2011.96.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Lyon AR, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229–361. https://doi.org/10.1093/eurheartj/ehac244.

Article  PubMed  Google Scholar 

Grinda T, et al. Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008–2017 ESME cohort. ESMO Open. 2021;6(3):100114. https://doi.org/10.1016/j.esmoop.2021.100114.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Belaroussi Y, et al. Survival outcomes of patients with metastatic non-small cell lung cancer receiving chemotherapy or immunotherapy as first-line in a real-life setting. Sci Rep. 2023;13(1):9584. https://doi.org/10.1038/s41598-023-36623-1.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Meegdes M, et al. Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2- metastatic breast cancer: an observational study of the SONABRE Registry. Lancet Reg Health Eur. 2023;26:100573. https://doi.org/10.1016/j.lanepe.2022.100573.

Article  PubMed  PubMed Central  Google Scholar 

Lewinter C, et al. A systematic review and meta-analysis of beta-blockers and renin-angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer. Eur Heart J. 2022;43(27):2562–9. https://doi.org/10.1093/eurheartj/ehab843.

Article  PubMed  CAS  Google Scholar 

Goulas K, et al. Cardioprotective agents for the primary prevention of trastuzumab-associated cardiotoxicity: a systematic review and meta-analysis. Pharmaceuticals (Basel). 2023;16(7):983. https://doi.org/10.3390/ph16070983.

Article  PubMed  CAS  Google Scholar 

Tarantini L, et al. Adjuvant trastuzumab cardiotoxicity in patients over 60 years of age with early breast cancer: a multicenter cohort analysis. Ann Oncol. 2012;23(12):3058–63. https://doi.org/10.1093/annonc/mds127.

Article  PubMed  CAS  Google Scholar 

Salem JE, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19(12):1579–89. https://doi.org/10.1016/S1470-2045(18)30608-9.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Osumi H, et al. Angiotensin II type-1 receptor blockers enhance the effects of bevacizumab-based chemotherapy in metastatic colorectal cancer patients. Mol Clin Oncol. 2015;3(6):1295–300. https://doi.org/10.3892/mco.2015.630.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Chu TF, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007;370(9604):2011–9. https://doi.org/10.1016/S0140-6736(07)61865-0.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Mitry MA, Edwards JG. Doxorubicin induced heart failure: Phenotype and molecular mechanisms. Int J Cardiol Heart Vasc. 2016;10:17–24. https://doi.org/10.1016/j.ijcha.2015.11.004.

Article  PubMed  Google Scholar 

Morelli MB, et al. Cardiotoxicity of anticancer drugs: molecular mechanisms and strategies for cardioprotection. Front Cardiovasc Med. 2022;9: 847012. https://doi.org/10.3389/fcvm.2022.847012.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Wang Y, et al. Cardiovascular toxicity associated with angiogenesis inhibitors: a comprehensive pharmacovigilance analysis based on the FDA adverse event reporting system database from 2014 to 2021. Front Cardiovasc Med. 2022;9:988013. https://doi.org/10.3389/fcvm.2022.988013.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Loibl S, et al. Early breast cancer: ESMO clinical practice Guideline for diagnosis, treatment and follow-up(dagger). Ann Oncol. 2023. https://doi.org/10.1016/j.annonc.2023.11.016.

Article  PubMed  Google Scholar 

Gennari A, et al. ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32(12):1475–95. https://doi.org/10.1016/j.annonc.2021.09.019.

Article  PubMed  CAS  Google Scholar 

Postmus PE, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv1–21. https://doi.org/10.1093/annonc/mdx222.

Article  PubMed  CAS  Google Scholar 

Hendriks LE, et al. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(4):358–76. https://doi.org/10.1016/j.annonc.2022.12.013.

Article  PubMed  CAS  Google Scholar 

Lordick F, et al. Gastric cancer: ESMO clinical practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):1005–20. https://doi.org/10.1016/j.annonc.2022.07.004.

Article  PubMed  CAS  Google Scholar 

Vogel A, et al. Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv238–55. https://doi.org/10.1093/annonc/mdy308.

Article  PubMed  CAS  Google Scholar 

Cervantes A, et al. Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(1):10–32. https://doi.org/10.1016/j.annonc.2022.10.003.

Article  PubMed  CAS  Google Scholar 

Powles T, et al. Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(3):244–58. https://doi.org/10.1016/j.annonc.2021.11.012.

Article  PubMed  CAS